AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15871313 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical eutectic mixture of local anesthetics (EMLA)
Number of subjects: 64
Study 15871313 — intervention group
Group type: COMPARATOR
Intervention: Topical lidocaine (LMX)
Number of subjects: 64
Study 12587324 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebivolol and enap
Number of subjects: 0
Study 10627088 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (TMZ)
Number of subjects: 0
Study 10627088 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study 10627088 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Letter Cancellation Task (3-LCT)
Number of subjects: 0
Study 10627088 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance of Wakefulness Test (MWT)
Number of subjects: 0
Study 10627088 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Sleep Latency Test (MSLT)
Number of subjects: 0
Study 8560052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 30
Study 8560052 — intervention group
Group type: COMPARATOR
Intervention: Control (no SNP)
Number of subjects: 30
Study 1785245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 39
Study 1785245 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 39
Study 7037505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine daily injections of fast‐acting insulin for ten days (group B)
Number of subjects: 15
Study 7037505 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with one or two daily doses of insulin (group A)
Number of subjects: 15
Study 30407055 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral app (Boost Me)
Number of subjects: 30
Study 30407055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive app (Thought Challenger)
Number of subjects: 30
Study 30407055 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study 28408018 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 1200
Study 28408018 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive strategy
Number of subjects: 1200
Study 25248020 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Inpatient Psychotherapy based on Transactional Analysis (STIP-TA)
Number of subjects: 134
Study 25248020 — intervention group
Group type: COMPARATOR
Intervention: Other Psychotherapies (OP)
Number of subjects: 134
Study 24331115 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 75 mg daily for 12 weeks
Number of subjects: 208
Study 24331115 — intervention group
Group type: COMPARATOR
Intervention: IVF‐ICSI without DHEA supplementation
Number of subjects: 208
Study 20934683 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchpad (familiar input device)
Number of subjects: 0
Study 20934683 — intervention group
Group type: COMPARATOR
Intervention: Mini-joystick (unfamiliar input device)
Number of subjects: 0
Study 20934683 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice (for novices)
Number of subjects: 0
Study 20934683 — intervention group
Group type: EXPERIMENTAL
Intervention: Touchpad
Number of subjects: 0
Study 20934683 — intervention group
Group type: COMPARATOR
Intervention: Mini-joystick
Number of subjects: 0
Study 19609178 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week behaviorally based intervention delivered in four 2-hour segments
Number of subjects: 122
Study 17556705 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fruit and vegetable consumption
Number of subjects: 4652
Study 17556705 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet scores
Number of subjects: 4652
Study 17556705 — intervention group
Group type: COMPARATOR
Intervention: Dairy products and Keys score
Number of subjects: 4652
Study 15455733 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg B.I.D. with scaling and root planing (SRP)
Number of subjects: 210
Study 15455733 — intervention group
Group type: COMPARATOR
Intervention: Placebo with scaling and root planing (SRP)
Number of subjects: 210
Study 11306234 — intervention group
Group type: EXPERIMENTAL
Intervention: BV treatment in high-risk women (previous preterm delivery)
Number of subjects: 7
Study 11306234 — intervention group
Group type: EXPERIMENTAL
Intervention: BV treatment in high-risk women (not having BV)
Number of subjects: 7
Study 11306234 — intervention group
Group type: COMPARATOR
Intervention: Routine BV screening and treatment
Number of subjects: 7
Study 9806702 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 9806702 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 20
Study 9806702 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 20
Study 8747858 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with late-onset Alzheimer's disease carrying allele epsilon 4
Number of subjects: 0
Study 8747858 — intervention group
Group type: COMPARATOR
Intervention: Patients with early-onset Alzheimer's disease
Number of subjects: 0
Study 8747858 — intervention group
Group type: COMPARATOR
Intervention: Patients with Parkinson's disease
Number of subjects: 0
Study 8747858 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals over 60 years
Number of subjects: 0
Study 2465708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015 microgram.kg‐1 pentamorphone
Number of subjects: 23
Study 2465708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 microgram.kg‐1 pentamorphone
Number of subjects: 23
Study 2465708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 microgram.kg‐1 pentamorphone
Number of subjects: 23
Study 2465708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 microgram.kg‐1 pentamorphone
Number of subjects: 23
Study 2465708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 microgram.kg‐1 pentamorphone
Number of subjects: 23
Study 2465708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.48 microgram.kg‐1 pentamorphone
Number of subjects: 23
Study 2465708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 811237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and oral bromhexine for 5 days
Number of subjects: 70
Study 811237 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bromhexine)
Number of subjects: 70
Study 811237 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and oral bromhexine for 5 days in high-risk patients
Number of subjects: 70
Study 811237 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-risk patients)
Number of subjects: 70
Study 30716557 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodies in Motion program
Number of subjects: 97
Study 30716557 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 97
Study 28988168 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid with information on overdetection
Number of subjects: 811
Study 28988168 — intervention group
Group type: COMPARATOR
Intervention: Decision aid without information on overdetection
Number of subjects: 811
Study 25331270 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull Energy drink (caffeine at 2 mg/kg body weight)
Number of subjects: 20
Study 25331270 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic, isovolumetric, noncaffeinated control drink (CD)
Number of subjects: 20
Study 23480978 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS‐DM2/RW (regular weight)
Number of subjects: 45
Study 23480978 — intervention group
Group type: COMPARATOR
Intervention: NBS‐DM2/NW (negligible weight)
Number of subjects: 45
Study 23480978 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Electromagnetic Fields (PEMF)
Number of subjects: 45
Study 21712623 — intervention group
Group type: EXPERIMENTAL
Intervention: APF gel application
Number of subjects: 0
Study 21712623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APF gel application)
Number of subjects: 0
Study 19350335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponseti treatment group
Number of subjects: 19
Study 19350335 — intervention group
Group type: COMPARATOR
Intervention: Control group (initial casting and posteromedial release)
Number of subjects: 19
Study 16689810 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based gels with varying glycerine concentrations and alcohol grades (70% ethanol)
Number of subjects: 0
Study 16689810 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopropanol-based gel
Number of subjects: 0
Study 15356963 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study 15356963 — intervention group
Group type: COMPARATOR
Intervention: Control (no NAC)
Number of subjects: 0
Study 11210871 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 90
Study 11210871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 6 microg/kg
Number of subjects: 90
Study 9313000 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral compression ultrasonography
Number of subjects: 1024
Study 9313000 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (placebo)
Number of subjects: 1024
Study 7905376 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml) given from twice to four times daily for 1-8 weeks
Number of subjects: 174
Study 7905376 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine eye drops (0.5 mg/ml)
Number of subjects: 174
Study 3066142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (intravenous treatment)
Number of subjects: 127
Study 3066142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 31815768 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 631
Study 31815768 — intervention group
Group type: COMPARATOR
Intervention: Open radical hysterectomy
Number of subjects: 631
Study 31305115 — intervention group
Group type: EXPERIMENTAL
Intervention: AWARE intervention (group psychotherapy)
Number of subjects: 63
Study 31305115 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 63
Study 28348182 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained Condylar Knee (CCK) design
Number of subjects: 170
Study 28348182 — intervention group
Group type: COMPARATOR
Intervention: Rotating Hinged (RTH) design
Number of subjects: 170
Study 26731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smokers (n = 27)
Number of subjects: 106
Study 26731869 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smokers (n = 32)
Number of subjects: 106
Study 26731869 — intervention group
Group type: COMPARATOR
Intervention: Not exposed to tobacco smoke (n = 41)
Number of subjects: 106
Study 23106907 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy protocol (mask with positive expiratory pressure of 10 cm H2O, expiratory rib cage compression, coughing, lifting upper limbs, ambulation, starting within 4 hours post-surgery, 3 times daily)
Number of subjects: 123
Study 23106907 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized physiotherapy protocol
Number of subjects: 123
Study 23106907 — intervention group
Group type: COMPARATOR
Intervention: Control group (physiotherapeutic techniques without standardization)
Number of subjects: 123
Study 22017069 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment with hydrogel patch
Number of subjects: 30
Study 22017069 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene 0.005%-betamethasone dipropionate 0.064% ointment without hydrogel patch
Number of subjects: 30
Study 18435781 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera, EXU) with standard care
Number of subjects: 739
Study 18435781 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (Group 2)
Number of subjects: 739
Study 21395928 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld computers for Health Management Information System data management
Number of subjects: 9880
Study 21395928 — intervention group
Group type: COMPARATOR
Intervention: Quality control laboratory results
Number of subjects: 9880
Study 15640382 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (three 400-kcal sessions per week at 60% of Vo(2 max))
Number of subjects: 64
Study 15640382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (three 400-kcal sessions per week at 80% of Vo(2 max))
Number of subjects: 64
Study 15640382 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexercise)
Number of subjects: 64
Study 15640382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 64
Study 12098040 — intervention group
Group type: EXPERIMENTAL
Intervention: TraumAID computer-generated management plans
Number of subjects: 97
Study 9688485 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of cefuroxime intravenously at cord clamping (n = 59)
Number of subjects: 120
Study 9688485 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (control group, n = 61)
Number of subjects: 120
Study 7865978 — intervention group
Group type: EXPERIMENTAL
Intervention: Onset hemodialysis (ON-HD) on a low-protein diet
Number of subjects: 96
Study 7865978 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-stage hemodialysis (ES-HD, 1-8 months)
Number of subjects: 96
Study 7865978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-stage hemodialysis (MS-HD, 9-69 months)
Number of subjects: 96
Study 7865978 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced-stage hemodialysis (AS-HD, 70-207 months)
Number of subjects: 96
Study 7865978 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (including ON-HD, ES-HD, MS-HD, AS-HD)
Number of subjects: 96
Study 2685676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile intravenous oxytocin infusion (every 8 minutes)
Number of subjects: 94
Study 2685676 — intervention group
Group type: COMPARATOR
Intervention: Continuous intravenous oxytocin infusion
Number of subjects: 94
Study 8663 — intervention group
Group type: EXPERIMENTAL
Intervention: bufuralol
Number of subjects: 55
Study 8663 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 55
Study 31646599 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 40
Study 31646599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29649805 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with a focus on physical exercise (CBT‐E)
Number of subjects: 173
Study 29649805 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with a focus on pleasurable, low‐energy and mindful activities (CBT‐M)
Number of subjects: 173
Study 29649805 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral analysis system of psychotherapy (CBASP)
Number of subjects: 173
Study 29649805 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 173
Study 27612574 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention consisting of 90min/week of physically active educational lessons, 5min/day of physical activity breaks, and 10min/day of physical activity homework.
Number of subjects: 1129
Study 27612574 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical activity intervention).
Number of subjects: 1129
Study 25124964 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group using 'TOPHAT655' unit with 21, 5 mW diode lasers (655 ± 5 nm) and 30 LEDs (655 ± 20 nm), treated at home every other day for 16 weeks (60 treatments, 67 J/cm² irradiance, 25 minute treatment, 2.9 J dose).
Number of subjects: 47
Study 25124964 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment group using an identical unit containing incandescent red lights.
Number of subjects: 47
Study 22448211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART levels of hsCRP
Number of subjects: 561
Study 22448211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART levels of D-dimer
Number of subjects: 561
Study 22448211 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ART levels of IL-6
Number of subjects: 561
Study 19330430 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise (3-4 days/week)
Number of subjects: 91
Study 19330430 — intervention group
Group type: EXPERIMENTAL
Intervention: High aerobic exercise (5-7 days/week)
Number of subjects: 91
Study 19330430 — intervention group
Group type: COMPARATOR
Intervention: Minimal aerobic exercise (0-2 days/week, control group)
Number of subjects: 91
Study 17488308 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (10 mg for 4 weeks, titrated to preferred dose of 5, 10, or 20 mg during the next 8 weeks, maintained at preferred dose for 14 weeks)
Number of subjects: 611
Study 17488308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 611
Study 17488308 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 611
Study 15040540 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour intervention in individual patients, in addition to standard of care
Number of subjects: 60
Study 15040540 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 60
Study 11374749 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group comparison with a lower status out-group
Number of subjects: 0
Study 11374749 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group comparison with a higher status out-group
Number of subjects: 0
Study 11374749 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated legitimacy of status differences
Number of subjects: 0
Study 11374749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational analyses
Number of subjects: 0
Study 9678530 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (0.1 IU/kg s.c.)
Number of subjects: 15
Study 7989455 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day)
Number of subjects: 17
Study 7989455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2729170 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (10 mg aspartame/kg)
Number of subjects: 23
Study 2729170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29720202 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard acquisition parameters with double dose (0.2 mmol/kg) Gadovist and 4 mm slice thickness.
Number of subjects: 40
Study 29720202 — intervention group
Group type: COMPARATOR
Intervention: Reduced, single dose of GBCA (n=10), half slice thickness (n=10), or on a 3T scanner (n=10).
Number of subjects: 40
Study 29720202 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D LGE CMR atrial scar imaging.
Number of subjects: 40
Study 28705252 — intervention group
Group type: EXPERIMENTAL
Intervention: PGx-guided treatment (n=155)
Number of subjects: 316
Study 28705252 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU, control group, n=161)
Number of subjects: 316
Study 26179186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with defibrillator
Number of subjects: 1267
Study 26179186 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1267
Study 24119702 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Golden Bifid, 3.5 g for 3 times per day) for 21 days
Number of subjects: 52
Study 24119702 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional treatment and enteral nutrition)
Number of subjects: 52
Study 20363036 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments delivered to patients
Number of subjects: 42
Study 20363036 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic trials with chemotherapy agents
Number of subjects: 42
Study 17483124 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa
Number of subjects: 15
Study 17483124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16478743 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin E (> 400 IU/day)
Number of subjects: 29361
Study 16478743 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental vitamin E (≥ 10 years of use)
Number of subjects: 29361
Study 16478743 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental beta-carotene (≥ 2000 microg/day)
Number of subjects: 29361
Study 16478743 — intervention group
Group type: COMPARATOR
Intervention: No supplemental vitamin E
Number of subjects: 29361
Study 16478743 — intervention group
Group type: COMPARATOR
Intervention: No supplemental beta-carotene
Number of subjects: 29361
Study 12233984 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent monetary reinforcement (CM) combined with 21 mg transdermal nicotine
Number of subjects: 42
Study 12233984 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent monetary reinforcement (CM) combined with placebo patch
Number of subjects: 42
Study 12233984 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent reinforcement combined with placebo patch
Number of subjects: 42
Study 10765866 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer materials
Number of subjects: 187
Study 10765866 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacid-modified resin composite
Number of subjects: 187
Study 10765866 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass-ionomer material
Number of subjects: 187
Study 7501142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated patients (carotid endarterectomy)
Number of subjects: 0
Study 7501142 — intervention group
Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 0
Study 7501142 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical therapy
Number of subjects: 0
Study 7501142 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 0
Study 7501142 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 0
Study 2176948 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 2176948 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 0